Computational chemistry
Modelled peptides inhibit SARS-CoV-2 main protease
Open access · cc by · source: Europe PMC
Simulations prefer a neutral His41/Cys145 dyad and guided four designed peptides that bind the Mpro dimer and inhibit substrate cleavage with IC50 values of 3–5 μM.
Study at a glance
- Design
- Other — Computational design plus biochemical IC50 assays of Mpro peptide inhibitors
- N
- Four designed peptides assayed in vitro — no sample cohort N
- Population
- SARS-CoV-2 main protease with designed peptide inhibitors
- Outcome
- Peptide IC50 values and substrate-depletion inhibition of Mpro
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
The ion-pair dyad lies 28.5 kJ mol−1 above the neutral state. Designed peptides have IC50 3.11–5.36 μM; at 8-fold excess they cut s01 depletion from >98% to 70–95%. Binding modes mimic cluster-5 fragments and H-bond His-163/Glu-166.
Methodology
Authors combined docking, MD, QM/MM and fragment clustering on SARS-CoV-2 Mpro, synthesised peptides p12, p13, p15 and p16, and measured inhibition and non-denaturing MS complexes versus 11-mer substrates.
Limitations
These are micromolar peptides, not optimized oral antivirals, and the preferred dyad protonation is a computed free-energy result.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
MD plus docking can design peptides that then meet a wet IC₅₀, which is a stronger claim than MD that cannot rank sites. SARS-CoV-2 Mpro peptides p12–p16 have IC₅₀ 3.11–5.36 μM; at 8-fold excess they cut s01 depletion from >98% to 70–95%; the ion-pair dyad lies 28.5 kJ mol⁻¹ above the neutral state. On dimethylated lysozyme, short MD at each Lys-Me₂ and a crystal of sclx4 encapsulating Lys116-Me₂ still left MM-PBSA unable to rank sites; precipitation limited solution stoichiometry.
Evidence for the claim as stated.
MD that is later tested in a cuvette is not the same deliverable as MD that stays inside the computer. Mpro peptides have micromolar IC₅₀ values; GFP AIMD proton-transfer times disagree with 3/10 ps FSRS phases; UiO-66 proton hops are invisible to time-averaged XRD. A student who says 'MD showed the mechanism' must say whether a wet observable confirmed it.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
MD that is later tested in a cuvette is not the same deliverable as MD that stays inside the computer. Mpro peptides have micromolar IC₅₀ values; GFP AIMD proton-transfer times disagree with 3/10 ps FSRS phases; UiO-66 proton hops are invisible to time-averaged XRD. A student who says 'MD showed the mechanism' must say whether a wet observable confirmed it.
- Supports · AIMD maps GFP's excited-state proton shuttle
- Supports · Defect hydroxides in UiO-66 shuttle protons
Related papers in this topic
Same topic cluster — not a recommendation engine.